(Q37733556)

22 August 2017

1 reference

title

Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction (English)

1 reference

22 August 2017

4

Wayne J G Hellstrom

1 reference

22 August 2017

Philip Dorsey

1

1 reference

22 August 2017

Christopher Keel

series ordinal

2

1 reference

22 August 2017

Meghan Klavens

series ordinal

3

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

Expert Opinion on Pharmacotherapy

22 August 2017

published in

1 reference

22 August 2017

volume

11

1 reference

22 August 2017

issue

7

1 reference

22 August 2017

page(s)

1109-1122

1 reference

Prevalence of erectile dysfunction: a systematic review of population-based studies.

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Haem-dependent activation of guanylate cyclase and cyclic GMP formation by endogenous nitric oxide: a unique transduction mechanism for transcellular signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Role of nitric oxide in the physiology of erection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Current and future trends in the oral pharmacotherapy of male erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Treatment for erectile dysfunction based on patient-reported outcomes: to every man the PDE5 inhibitor that he finds superior

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

2009 update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

The efficacy and safety of udenafil, a new selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

The efficacy and safety of udenafil [Zydena] for the treatment of erectile dysfunction in hypertensive men taking concomitant antihypertensive agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Increased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical diabetogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Determination of mirodenafil and sildenafil in the plasma and corpus cavernous of SD male rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Tadalafil is efficacious and well tolerated in the treatment of erectile dysfunction (ED) in men over 65 years of age: results from Multiple Observations in Men with ED in National Tadalafil Study in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Pathophysiology and treatment of diabetic erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Negative impact of metabolic syndrome on the responsiveness to sildenafil in Japanese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

The functional and structural consequences of cavernous nerve injury are ameliorated by sildenafil citrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Pathophysiology of erectile dysfunction: the contributions of trabecular structure to function and the role of functional antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Statistical evaluation of hemodynamic effects of regular use of sildenafil on the human corpora cavernosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Serum biomarker measurements of endothelial function and oxidative stress after daily dosing of sildenafil in type 2 diabetic men with erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Effects of phosphodiesterase inhibitors on the contractile responses of isolated human seminal vesicle tissue to adrenergic stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Effects of vardenafil administration on intravaginal ejaculatory latency time in men with lifelong premature ejaculation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

2009 update on phosphodiesterase type 5 inhibitor therapy part 1: Recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications (CME).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Combination of doxazosin and sildenafil exerts an additive relaxing effect compared with each compound alone on human cavernosal and prostatic tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Combination of alfuzosin and tadalafil exerts in vitro an additive relaxant effect on human corpus cavernosum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

The effect of sildenafil citrate on bladder outlet obstruction: a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Effects of chronic treatment with vardenafil, a phosphodiesterase 5 inhibitor, on female rat bladder in a partial bladder outlet obstruction model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Sildenafil citrate therapy for pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Effect of sildenafil on acrolein-induced airway inflammation and mucus production in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Role of sildenafil in neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Tadalafil improves short-term memory by suppressing ischemia-induced apoptosis of hippocampal neuronal cells in gerbils

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Sildenafil citrate as a phosphodiesterase inhibitor has an antioxidant effect in the blood of men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

The effect of generic competition on the price of brand-name drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Patients' perceptions of generic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Counterfeit medicines. Bitter pills

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

An unusual outbreak of hypoglycemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Nerve-induced release of nitric oxide from the rabbit corpus cavernosum is modulated by cyclic guanosine 3',5'-monophosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

A-350619: a novel activator of soluble guanylyl cyclase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

Dose-dependent pharmacokinetics and first-pass effects of mirodenafil, a new erectogenic, in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003698131

10.1517/14656561003698131

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference